SCHEMBL8006342

SCHEMBL8006342

CC1(C)C(=O)N(c2ccc(S(C)(=O)=O)cc2Cl)C(=O)N1Cc1ccccc1Oc1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
PTGS2 P35354 2/20 0.37
IGF1R P08069 1/20 0.36
TAS2R8 Q9NYW2 2/20 0.35
NR1H2 P55055 1/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
FAAH O00519 1/20 0.34
BRD4 O60885 3/20 0.34
SLC6A4 P31645 3/20 0.34
HTR2A P28223 2/20 0.34
KCNH2 Q12809 1/20 0.34
PTGS1 P23219 1/20 0.34
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8023329 0.88 SLC6A4 (0.41) HDAC1HDAC6TAS2R8FAAHSLC6A4
SCHEMBL8001609 0.85 HDAC1 (0.45) HDAC1HDAC6TAS2R8NR1H2POLB
SCHEMBL1773206 0.84 GLA (0.38) HDAC1HDAC6PTGS2IGF1RTAS2R8
SCHEMBL8023332 0.82 SLC6A4 (0.41) HDAC1HDAC6TAS2R8NR1H2FAAH
SCHEMBL8000922 0.81 SLC6A4 (0.42) HDAC1HDAC6TAS2R8L3MBTL1FAAH
SCHEMBL12873244 0.81 HDAC1 (0.48) HDAC1HDAC6TAS2R8NR1H2FAAH
SCHEMBL8016194 0.81 SLC6A4 (0.42) HDAC1HDAC6TAS2R8NR1H2FAAH
SCHEMBL8021527 0.81 HDAC1 (0.43) HDAC1HDAC6TAS2R8NR1H2L3MBTL1
SCHEMBL8010634 0.79 TAS2R8 (0.44) HDAC1HDAC6IGF1RTAS2R8NR1H2
SCHEMBL1190966 0.79 IGF1R (0.39) HDAC1HDAC6IGF1RTAS2R8FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046185-A1 Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof SANOFI-AVENTIS (FR) 2011-02-24 US disclosed
US-20110046185-A1 Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof SANOFI-AVENTIS (FR) 2011-02-24 US disclosed
WO-2009097998-A1 ARYLCHALCOGENO-ARYLALKYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF SANOFI-AVENTIS (FR) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046185-A1 Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof PGC, LIPC, CEL HDAC1 1393/4885HDAC6 2952/4885PTGS2 665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.